Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...
Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...
Novo Nordisk launched Wegovy in India in June, three months after Eli Lilly introduced its competing weight-loss product ...
Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...
Explore how the rise of weight-loss drugs in India may seem like a quick fix but carry serious health risks. We uncover seven ...
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...
India Today on MSN
Novo Nordisk partners with Emcure to expand Wegovy's reach in India
Wegovy, which uses semaglutide to aid weight loss, was introduced in India in June 2024, two months after Mounjaro's debut.
Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.
Now, it’s worth noting Stock Advisor’s total average return is 1,036% — a market-crushing outperformance compared to 191 % ...
Weight loss drugs like Zepbound and Wegovy will become more accessible to millions of Americans after the Trump ...
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback